ÂÜÀòÂÒÂ×

Mr. Landau has over 20 years of biopharmaceutical experience in corporate development, corporate strategy and new product strategy/planning. Most recently, Mr. Landau was senior vice president, corporate development, commercial and new product strategy at Catalyst Biosciences, Inc., where he was a member of the executive management team responsible for partnering, license & acquisition, corporate strategy, pipeline and new product planning, alliance and project management. Prior to joining Catalyst, Mr. Landau held corporate development and global product and pipeline strategy roles of increasing responsibility at Threshold Pharmaceuticals and Onyx Pharmaceuticals (acquired by Amgen). Mr. Landau received his M.B.A. from Stanford Graduate School of Business and his B.S. In Honors in Biochemistry/Biotechnology from Virginia Polytechnic Institute.